Integrin αvβ3

Class

αvβ3 integrin-targeted small-molecule-drug conjugate (SMDC), neutrophil-elastase-activated camptothecin (topoisomerase I inhibitor) payload. NOTE: input modality field 'biologic conjugate' is imprecise — this is a small-molecule (non-antibody) conjugate.

Pathway

Integrin-mediated tumor targeting; topoisomerase I inhibition

Integrin αvβ3 is a cell-surface adhesion receptor formed by pairing of the αv and β3 protein chains. It binds proteins in the extracellular matrix that contain a specific amino-acid motif (RGD), and through this binding it helps cells attach, migrate, and survive. It is expressed at low levels on most normal tissue but becomes markedly upregulated on the blood vessels that tumors recruit to support their growth (tumor angiogenesis) and on the surface of many tumor cells themselves. This differential expression makes αvβ3 an attractive homing point for delivering therapy selectively to tumors rather than throughout the body. The mechanism described here uses a small molecule (not an antibody) that mimics the RGD motif to bind αvβ3, chemically linked to a potent topoisomerase I inhibitor of the camptothecin class, which blocks an enzyme cells need to correctly manage DNA structure during replication. The linker connecting the two components is designed to be cut only by neutrophil elastase, an enzyme found in elevated concentration around tumor tissue. This combination of receptor-directed delivery and local enzymatic release is intended to concentrate cytotoxic activity where the integrin and the activating enzyme coincide, a strategy relevant across cancers marked by active angiogenesis or elastase-rich tumor microenvironments.